Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 12/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | USP2 | O75604 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22856361 | 0.85 | CYP2D6 (0.51) | TSHRCYP2D6SMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL24508472 | 0.83 | CYP2D6 (0.37) | TSHRCYP2D6SMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL22305065 | 0.80 | TSHR (0.53) | TSHRCYP2D6CYP3A4 | |
| SCHEMBL25728844 | 0.78 | DRD2 (0.33) | CYP2D6SMN1; SMN2 | |
| SCHEMBL10289113 | 0.78 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL15221484 | 0.77 | TSHR (0.61) | TSHRCYP2D6CYP3A4VNN1 | |
| SCHEMBL23842142 | 0.77 | CYP2D6 (0.32) | TSHRCYP2D6 | |
| SCHEMBL24250659 | 0.77 | TSHR (0.49) | TSHRCYP2D6SMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL23560331 | 0.77 | CYP2D6 (0.48) | TSHRCYP2D6SMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL25924590 | 0.76 | CYP2D6 (0.37) | CYP2D6SMN1; SMN2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TSHR 3319/4885CYP2D6 3599/4885SMN1; SMN2 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.